Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

🇨🇳 Laotian Times (CN) —

AI Summary

China’s National Medical Products Administration has accepted Lynk Pharmaceuticals’ application for zemprocitinib capsules to treat moderate-to-severe active rheumatoid arthritis. Acceptance marks a regulatory review milestone, not an approval to market the drug.

SHANGHAI and HANGZHOU, China and BOSTON, Nov. 6, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (“Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe active rheumatoid arthritis (RA) was formally accepted by […]

Markets Health Lynk Pharmaceuticals zemprocitinib rheumatoid arthritis drug application NMPA China

Read original source →